Other Mutations: CTNNB1

NCT04851119: Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: APC, AXIN2, RNF43, GSK3B, CTNNB1
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 30 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients must have a tumor with Wnt pathway aberrations including the most common CTNNB1 mutations as well as any loss of function mutations in the APC, Axin2FBXW7, TCF7L2, & RNF43 genes, or any gain-of-function mutations in the GSK3B, LRP6, & LGR5 genes
Exclusions: 
https://ClinicalTrials.gov/show/NCT04851119

Up ↑